Cantor Fitzgerald Predicts PLRX FY2025 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Pliant Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($1.51) for the year. Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.64) per share.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.17.

Several other equities analysts have also issued reports on PLRX. Leerink Partners lowered shares of Pliant Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $33.00 to $2.00 in a report on Monday. HC Wainwright reissued a “neutral” rating on shares of Pliant Therapeutics in a research note on Tuesday. Royal Bank of Canada decreased their target price on Pliant Therapeutics from $4.00 to $3.00 and set a “sector perform” rating for the company in a research note on Tuesday. Wells Fargo & Company dropped their price target on Pliant Therapeutics from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, Stifel Nicolaus downgraded shares of Pliant Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday. Twelve investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $13.31.

Pliant Therapeutics Stock Up 12.6 %

Pliant Therapeutics stock opened at $1.52 on Thursday. The firm has a market cap of $92.50 million, a price-to-earnings ratio of -0.46 and a beta of 1.18. Pliant Therapeutics has a 52-week low of $1.26 and a 52-week high of $16.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. The firm has a 50 day moving average price of $8.60 and a two-hundred day moving average price of $11.66.

Insider Transactions at Pliant Therapeutics

In other news, General Counsel Mike Ouimette sold 10,230 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total value of $112,427.70. Following the completion of the sale, the general counsel now directly owns 70,544 shares of the company’s stock, valued at $775,278.56. This represents a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bernard Coulie sold 52,419 shares of Pliant Therapeutics stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $587,092.80. Following the transaction, the chief executive officer now directly owns 430,517 shares in the company, valued at approximately $4,821,790.40. The trade was a 10.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 91,855 shares of company stock valued at $1,026,628 over the last three months. Corporate insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pliant Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its holdings in Pliant Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,903 shares of the company’s stock valued at $170,000 after buying an additional 1,209 shares in the last quarter. Swiss National Bank boosted its stake in shares of Pliant Therapeutics by 1.6% in the 4th quarter. Swiss National Bank now owns 95,700 shares of the company’s stock valued at $1,260,000 after purchasing an additional 1,500 shares in the last quarter. Atria Investments Inc grew its holdings in shares of Pliant Therapeutics by 18.1% during the 4th quarter. Atria Investments Inc now owns 11,821 shares of the company’s stock valued at $156,000 after purchasing an additional 1,812 shares during the last quarter. R Squared Ltd purchased a new position in Pliant Therapeutics in the 4th quarter worth $33,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Pliant Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company’s stock worth $6,050,000 after purchasing an additional 2,721 shares during the last quarter. 97.30% of the stock is owned by institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.